Relationship of bone turnover to bone density and fractures.
about
The Lichfield bone study: the skeletal response to exercise in healthy young menBone quality: an empty term.Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnoverNational Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.The assessment of fracture risk.Evaluating the relationship between muscle and bone modeling response in older adults.Progesterone and bone: actions promoting bone health in women.Trabecular bone deficits among Vietnamese immigrants.Osteoarthritis and bone mineral density: are strong bones bad for joints?Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosisAge-related effect on the concentration of collagen crosslinks in human osteonal and interstitial bone tissue.Associations of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D With Bone Mineral Density, Bone Mineral Density Change, and Incident Nonvertebral Fracture.Prevention and treatment of osteoporosis in inflammatory bowel disease.Impact and risk factors of post-stroke bone fracture.Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study.Bone quality: what is it and how is it measured?Clinical application of biochemical markers of bone turnover.Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal womenA hospital based study of biochemical markers of bone turnovers & bone mineral density in north Indian women.Relationship Between Urinary Cross-Linked N-Telopeptide of Type-I Collagen and Heel Stiffness Index Measured by Quantitative Ultrasound in Middle-Aged and Elderly MenAffective Disorders, Bone Metabolism, and Osteoporosis.Biomarkers of bone health and osteoporosis risk.Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density.Premenopausal Trabecular Bone Loss is Associated with a Family History of Fragility Fracture.Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra.Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis.Effects of collagen hydrolysate on the tibialis anterior muscle and femur in senescence-accelerated mouse prone 6.Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway.Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options.Denosumab and the current status of bone-modifying drugs in breast cancer.Bone mineral density and metabolism at an early stage of menopause when estrogen and calcium supplement are not used and without the interference of major confounding variables.The effect of age, weight, and lifestyle factors on calcaneal quantitative ultrasound: the ESOPO study.The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60.Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis.Kefir improves bone mass and microarchitecture in an ovariectomized rat model of postmenopausal osteoporosis.The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status.Differential characteristics of bone quality and bone turnover biochemical markers in patients with hip fragility fractures and hip osteoarthritis: results of a clinical pilot study.An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by F
P2860
Q30458203-0011E786-91B2-4CE4-B914-67E70A04CFFAQ33277096-31800AB6-5AE5-4492-BF77-6E465FBE76EFQ33572186-09CA620A-07B6-4FAF-B5EC-7B8C8F8D5A24Q33572610-5246FECE-D074-4944-8A8A-72FE3E48B58CQ33685092-D61295AF-B4AA-41C8-9B9C-F01D414FEDB4Q33864893-16A00B0E-9EB5-4C19-BE22-2FB1BCB26A54Q34261512-870A997B-2CA4-4089-B2EA-AD3896A16DF8Q34978391-E3165F3A-5E9D-44D1-9861-86F2AF887778Q35000946-BBA9F12C-667F-4DCF-89CE-AEA522AF60EEQ35026446-7B438F1C-8BE8-4490-A0D4-D7E5ECCB9F4DQ35053491-977B2AC9-8138-4F07-8056-028A62B0623CQ35741491-CDFD8856-0D81-4081-8360-2B0909212D51Q35864004-EC5B9EF7-7D39-42B1-917B-EC89BB26E3A9Q36569260-27512554-E940-440B-A144-6E814BC7A125Q36594973-81F28177-C7C7-4F5B-9902-DD9F3998CA72Q36606767-9C22DAAF-90D1-400D-B6CB-9199F179D6B6Q36658905-587EFEF0-8E4C-4091-A138-642E1CEEE612Q36658915-123CF966-9D31-42DF-B649-978B0645BBFFQ36692024-059CF2C8-FD86-42BF-B45D-F041FD5AEB0FQ36855629-353D84F4-1BA5-45C9-9F45-23AFDA9952C1Q37026119-45CFEE3F-122F-4F09-8EAF-1B498F64776BQ37027277-D7846C3C-D2A5-4BB0-972F-16C79CED8641Q37138648-9585C19C-E584-413D-9530-283B1A18991DQ37178686-728A8440-78AB-4F53-A5B7-5AA4A054DC28Q37210322-91923898-94BC-4E00-A557-F2CD7D2B2FDFQ37233308-175D3B71-C021-4BB7-B378-75C43A71EB84Q37250572-DFBCF863-D8D6-4B46-A214-950ADDC90EADQ37290052-73156F1B-639F-43EF-A905-D8BE0710641BQ37421350-1F6A44E2-9990-4AB9-8C13-DFDF7888B20DQ37728708-A1C3A16D-CAD7-4E89-95BC-B5E183A91864Q37951107-45782A53-61AD-4EA9-99D6-1DF4E199A362Q37965768-45B32046-30A6-4A17-874E-44B41FFF0478Q38512855-C48A9ADD-678F-4201-9F35-B48A70574217Q38520441-0630BBBD-1E40-46F5-9099-7614D21C423DQ38527424-9C487186-1AED-424A-91DF-6D58AB307C77Q38555331-18C9CEFB-32FE-4E42-852D-8816E896E35BQ38950930-7F6227FF-9011-421F-84C3-5E338E1746D5Q43584229-18F9FDC2-33C7-4451-9A5A-6233906D715EQ44375703-EF747173-CA98-46E0-A429-8B99E9037EB4Q44662093-110AB6FE-6F7B-4920-9E5D-EAFB74BA1301
P2860
Relationship of bone turnover to bone density and fractures.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Relationship of bone turnover to bone density and fractures.
@ast
Relationship of bone turnover to bone density and fractures.
@en
Relationship of bone turnover to bone density and fractures.
@nl
type
label
Relationship of bone turnover to bone density and fractures.
@ast
Relationship of bone turnover to bone density and fractures.
@en
Relationship of bone turnover to bone density and fractures.
@nl
prefLabel
Relationship of bone turnover to bone density and fractures.
@ast
Relationship of bone turnover to bone density and fractures.
@en
Relationship of bone turnover to bone density and fractures.
@nl
P2093
P1476
Relationship of bone turnover to bone density and fractures.
@en
P2093
Atkinson EJ
Melton LJ 3rd
O'Fallon WM
P2860
P304
P356
10.1359/JBMR.1997.12.7.1083
P577
1997-07-01T00:00:00Z